Physician profile
Amrit Kumar
NPI 1003166364
$15,563.77
in general payments reported to CMS, 2019-2025
32 companies · $5,506 in 2025
The $5,506 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,944 · 2022: $2,315 · 2023: $2,369 · 2024: $3,429 · 2025: $5,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,867 · Consulting Fee: $1,000 · Travel and Lodging: $250 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,867.08 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $250.00 |
| Education | $187.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $3,160.87 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $1,538.99 | 2021-2025 | |
| Abbvie INC. | $1,132.63 | 2021-2025 | |
| Janssen Biotech, INC. | $1,106.41 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Leo Pharma INC. | $857.38 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $775.91 | 2021-2025 | Opzelura, Opzelura |
| Mayne Pharma Commercial LLC | $673.59 | 2021-2023 | |
| Galderma Laboratories, L.P. | $656.41 | 2021-2025 | Aklief, Nemluvio, Dysport |
| Sun Pharmaceutical Industries INC. | $627.05 | 2021-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $606.13 | 2021-2025 | Otezla, Otezla |
| Almirall LLC | $525.98 | 2021-2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $515.24 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $475.27 | 2022-2025 | Sotyktu |
| Ucb, INC. | $452.27 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $436.99 | 2022-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $426.09 | 2021-2025 | |
| Pfizer INC. | $417.26 | 2021-2025 | |
| Lilly USA, LLC | $323.55 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Vyne Pharmaceuticals INC. | $212.70 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.29 | 2021-2025 | Cabtreo, Siliq, Duobrii |
| Organon LLC | $118.45 | 2025 | Vtama |
| Journey Medical Corporation | $79.58 | 2022-2023 | |
| Allegis Pharmaceuticals, LLC | $62.96 | 2022 | |
| Verrica Pharmaceuticals INC. | $46.31 | 2023-2024 | Ycanth |
| Epi Health, LLC | $37.47 | 2021-2022 | |
| Botanix Sb INC | $36.42 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $26.40 | 2025 | Valchlor |
| Cipher Pharmaceuticals US LLC | $23.21 | 2025 | Natroba, Spinosad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.75 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $16.45 | 2022 | |
| Sebela Pharmaceuticals INC. | $16.07 | 2022 | |
| Strata Skin Sciences, INC. | $14.69 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrit Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.